Cerliponase alfa FDA approved to slow loss of ambulation in children of all ages with CLN2 disease
July 25th 2024From baseline to final assessment, all 7 matched cerliponase alfa-treated children under 3 years of age maintained a motor score of 3, representing a "grossly normal gait, signifying a delay in disease onset," stated BioMarin.